Compare AERT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | LSTA |
|---|---|---|
| Founded | 2012 | 1980 |
| Country | Singapore | United States |
| Employees | 1400 | N/A |
| Industry | Professional Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | AERT | LSTA |
|---|---|---|
| Price | $6.35 | $3.45 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 406.4K | 96.3K |
| Earning Date | 02-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.26 | $1.81 |
| 52 Week High | $6.90 | $5.07 |
| Indicator | AERT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 89.16 | 49.77 |
| Support Level | $0.45 | $3.06 |
| Resistance Level | N/A | $3.67 |
| Average True Range (ATR) | 0.32 | 0.18 |
| MACD | 0.60 | 0.03 |
| Stochastic Oscillator | 90.56 | 35.11 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.